| Enhanced cancer immunotherapy by chimeric antigen receptor–modified T cells engineered to secrete checkpoint inhibitors SI Li, N Siriwon, X Zhang, S Yang, T Jin, F He, YJ Kim, J Mac, Z Lu, ... Clinical cancer research 23 (22), 6982-6992, 2017 | 290 | 2017 |
| Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity Y Liu, J Fang, YJ Kim, MK Wong, P Wang Molecular pharmaceutics 11 (5), 1651-1661, 2014 | 171 | 2014 |
| CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction N Siriwon, YJ Kim, E Siegler, X Chen, JA Rohrs, Y Liu, P Wang Cancer immunology research 6 (7), 812-824, 2018 | 132 | 2018 |
| Creatine uptake regulates CD8 T cell antitumor immunity S Di Biase, X Ma, X Wang, J Yu, YC Wang, DJ Smith, Y Zhou, Z Li, YJ Kim, ... The Journal of experimental medicine 216 (12), 2869, 2019 | 90 | 2019 |
| Combination cancer therapy using chimeric antigen receptor-engineered natural killer cells as drug carriers EL Siegler, YJ Kim, X Chen, N Siriwon, J Mac, JA Rohrs, PD Bryson, ... Molecular Therapy 25 (12), 2607-2619, 2017 | 88 | 2017 |
| Synthesis, optimization, and characterization of camptothecin-loaded acetalated dextran porous microparticles for pulmonary delivery SA Meenach, YJ Kim, KJ Kauffman, N Kanthamneni, EM Bachelder, ... Molecular pharmaceutics 9 (2), 290-298, 2012 | 87 | 2012 |
| Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy YR Li, Y Zhou, YJ Kim, Y Zhu, F Ma, J Yu, YC Wang, X Chen, Z Li, S Zeng, ... Cell Reports Medicine 2 (11), 2021 | 65 | 2021 |
| Nanomedicine targeting the tumor microenvironment: Therapeutic strategies to inhibit angiogenesis, remodel matrix, and modulate immune responses EL Siegler, YJ Kim, P Wang Journal of Cellular Immunotherapy 2 (2), 69-78, 2016 | 62 | 2016 |
| Co-eradication of breast cancer cells and cancer stem cells by cross-linked multilamellar liposomes enhances tumor treatment YJ Kim, Y Liu, S Li, J Rohrs, R Zhang, X Zhang, P Wang Molecular pharmaceutics 12 (8), 2811-2822, 2015 | 60 | 2015 |
| Designed ankyrin repeat proteins as Her2 targeting domains in chimeric antigen receptor-engineered T cells E Siegler, S Li, YJ Kim, P Wang Human gene therapy 28 (9), 726-736, 2017 | 59 | 2017 |
| Targeting monoamine oxidase A for T cell–based cancer immunotherapy X Wang, B Li, YJ Kim, YC Wang, Z Li, J Yu, S Zeng, X Ma, IY Choi, ... Science immunology 6 (59), eabh2383, 2021 | 42 | 2021 |
| Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature Y Liu, YJ Kim, N Siriwon, JA Rohrs, Z Yu, P Wanga Biotechnology and Bioengineering 115 (6), 1403-1415, 2018 | 34 | 2018 |
| Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment WP Zhang X, Liu Y, Kim YJ, Mac J, Zhuang R RSC Adv. 7, 19685-19693, 2017 | 34 | 2017 |
| Nanoformulation improves antitumor efficacy of MAOI immune checkpoint blockade therapy without causing aggression-related side effects J Brown, Z Li, X Wang, YJ Kim, YC Wang, Y Zuo, W Hong, P Wang, B Li, ... Frontiers in Pharmacology 13, 970324, 2022 | 2 | 2022 |
| Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers P Wang, E Siegler, X Chen, YJ Kim US Patent App. 16/609,443, 2020 | 1 | 2020 |
| Adoptive transfer of car t cells with surface-conjugated drug-loaded nanoparticles and uses thereof P Wang, YJ Kim, N Siriwon US Patent App. 16/485,033, 2019 | | 2019 |
| Enhanced Cancer Immunotherapy By Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors N Siriwon, S Li, YJ Kim, P Wang 2017 AIChE Annual Meeting, 2017 | | 2017 |
| Optimization of Nanomedicine Based Drug Delivery Systems for the Treatment of Solid Tumors YJ Kim University of Southern California, 2017 | | 2017 |
